Vnitr Lek 2025, 71(4):207-212

Hlavní téma: Pneumologie up-to-date

Vladimír Koblížek
Plicní klinika FN HK a LF HK UK

Published: June 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koblížek V. Hlavní téma: Pneumologie up-to-date. Vnitr Lek. 2025;71(4):207-212.
Download citation

References

  1. Chronic respiratory diseases. Data from 2025. WHO. Anotace. [cit. 2025-05-18]. Available from: .
  2. Májek, O., Koziar Vašáková, M., Čierna Peterová, I., et al. PrevenceProPlice.cz - Program časného záchytu karcinomu plic. Praha: Ústav zdravotnických informací a statistiky ČR, 2022. [cit. 2025-05-18]. Available from:
  3. Ward B, Koziar Vašáková M, Robalo Cordeiro C, et al. Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer screening. ERJ Open Res. 2023;9(3):00026-2023. doi: 10.1183/23120541.00026-2023. Go to original source... Go to PubMed...
  4. Althobiani MA, Russell AM, Jacob J, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med. 2024;11:1296890. doi: 10.3389/fmed.2024.1296890. Go to original source... Go to PubMed...
  5. Venkatesan P. GOLD COPD report: 2025 update. Lancet Respir Med. 2025;13(1):e7-e8. doi: 10.1016/S2213-2600(24)00413-2. Go to original source... Go to PubMed...
  6. Matera MG, Rinaldi B, Annibale R, et al. The pharmacological management of asthma in adults: 2023 update. Expert Opin Pharmacother. 2024;25(4):383-393. doi: 10.1080/14656566.2024.2332627. Go to original source... Go to PubMed...
  7. Horváth I, Canotilho M, Chlumský J, et al. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1):00171-2018. doi: 10.1183/23120541.00171-2018. Go to original source... Go to PubMed...
  8. Fila L. Cystická fibróza dospělých. Vnitř Lék. 2017; 63(11):834-842. Go to original source...
  9. Keating C, Yonker LM, Vermeulen F et al; VX20-121-102 Study Group; VX20-121-103 Study Group. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025; 13(3):256-271. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.